Recent Updates
Recently added Catalysts
BBIO

BridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential Of Low-dose Infigratinib In Achondroplasia

Monday, May 11, 2020 1 min read
Key Takeaway: BridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential Of Low-dose Infigratinib In Achondroplasia

Full Press Release Details

BridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential Of Low-dose Infigratinib In Achondroplasia.
Tags: BBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 11, 2020